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ABSTRACT
Purpose: Regorafenib, an oral multikinase inhibitor, has demonstrated survival 
benefit in metastatic colorectal cancer (mCRC) patients that have progressed after 
all standard therapies. However, novel strategies to improve tolerability and enhance 
anti-cancer efficacy are needed.
Experimental design: We have evaluated in vitro the effects of regorafenib in 
combination with silybin, a biologically active component extracted from the seeds 
of Silybum marianum, in a panel of human colon cancer cells. Furthermore, we have 
prospectively treated a cohort of 22 refractory mCRC patients with regorafenib plus 
silybin. 
Results: Treatment with regorafenib determined a dose-dependent growth 
inhibition whereas treatment with silybin had no anti-proliferative effects among 
all cancer cells tested. The combined treatment with regorafenib and silybin 
induced synergistic anti-proliferative and apoptotic effects by blocking PI3K/AKT/
mTOR intracellular pathway. Moreover, combined treatment with regorafenib and 
silybin increased the production of reactive oxygen species levels within cells. In 
an exploratory proof of concept clinical study in a cohort of 22 mCRC patients after 
failure of all standard therapies, the clinical activity of regorafenib in combination 
with silybin was assessed. A median progression-free survival of 10.0 months and 
a median overall survival of 17.6 months were observed in these patients. These 
results suggest that the combined treatment potentially increases the clinical efficacy 
of regorafenib. Moreover, due to its anti-oxidative properties, silybin could protect 
patients from drug-induced liver damages, allowing to continue an effective anti-
cancer therapy.
Conclusions: The present study suggests that silybin in combination with 
regorafenib is a promising strategy for treatment of metastatic colorectal patients.
                                                        Research Paper
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INTRODUCTION
Novel advances in metastatic colorectal cancer 
(mCRC) therapies have led over the last two decades to 
an increase in median overall survival (OS) of patients 
from 12 months, during the 5-fluoruracil (5-FU)-based 
chemotherapy era to approximately 30 months due to 
development of new therapeutic agents [1–2]. In this 
scenario, regorafenib is an oral multikinase inhibitor that 
targets different protein kinases involved in key oncogenic 
pathways, such as angiogenesis by blocking vascular 
endothelial growth factor receptor-1 (VEGFR-1), 2 and 
3 and tyrosine kinases, immunoglobulin and epidermal 
growth factor (EGF) homology domain 2 (TIE-2) tyrosine 
kinase; such as tumor progression by inhibition KIT, RET, 
RAF-1 and BRAF; and such as tumor microenvironment 
by blocking platelet derived growth factor receptor-β 
(PDGR-β) and fibroblast growth factor receptor (FGFR) 
tyrosine kinases [3–4]. Two phases III clinical trials 
(CORRECT and CONCUR) have demonstrated in heavily 
pre-treated mCRC patients a significant improvement 
in OS and in progression free survival (PFS) with 
regorafenib as compared to placebo [5–6]. Despite the 
advantage in survival, very few objective responses have 
been reported with the main effect consisting in disease 
stabilization [5–7]. Based on these results, regorafenib has 
been approved by the European Medicines Agency (EMA) 
and the Food and Drug Administration (FDA) for the 
treatment of chemorefractory mCRC patients. However, 
the toxicity profile, including liver toxicity, fatigue and 
hand and foot skin reactions (HFSR), has limited drug use 
in clinical practice [8]. These concerns have produced an 
urgent need for the identification of compounds that are 
able to limit regorafenib side effects and, therefore, for 
improving regorafenib tolerability and, at the same time, 
enhancing its clinical activity. In this scenario, silybin is a 
biological active compound that is extracted from the milk 
thistle seeds of Silybum marianum, which has been shown 
to have anti-inflammatory and anti-oxidative effects in the 
treatment of liver diseases, such hepatitis and cirrhosis 
[9–10]. Moreover, in the last two decades, silybin has 
shown anti-cancer effects against several types of tumor 
models, mainly through targeting cancer cell proliferation, 
metabolism, apoptosis, inflammation, or angiogenesis 
[11–19]. Silybin has been conjugated with vitamin E 
and phospholipids to improve the bioavailability, that 
is lower when pure silybin is administered orally, and, 
therefore, its antioxidant activity (RealSiL). In this 
formulation, it has been proposed as a potential agent 
for reducing drug-induced liver damage [20–22]. Based 
on these considerations, we have performed an in vitro 
study to evaluate the ability of silybin in combination with 
regorafenib to inhibit the growth and induce apoptosis in 
a panel of human colon cancer cell lines. Furthermore, 
we have explored the potential clinical role of combined 
treatment in a prospective cohort of 22 mCRC patients that 
have progressed following administration of all available 
standard therapies.
RESULTS
Sensitivity to regorafenib and silybin treatment 
in a panel of human colon cancer cell lines
To evaluate the anti-proliferative effects of 
regorafenib and silybin treatment, as single agents, we 
have selected ten human colon cancer cell lines (LoVo, 
HCT15, SW48, SW48-CR, GEO, GEO-CR, SW620, 
SW480, HCT116 and LIM1215) that have distinct 
mutation profiles in KRAS, NRAS, BRAF, and PIK3CA 
genes. In particular, SW48 and LIM1215 cancer cells, that 
are wild type (WT) for KRAS, BRAF, NRAS and PIK3CA 
genes, and GEO cancer cells, that have a KRAS codon 
12 mutation, are sensitive to the anti-epidermal growth 
factor receptor (EGFR) monoclonal antibody cetuximab 
[23]. Despite GEO cells harbors a KRAS gene mutation, 
previous studies from different laboratories including our 
own, have demonstrated that this cancer cell line is one of 
the most sensitive to in vitro and in vivo anti-tumor activity 
of cetuximab treatment [24]. Moreover, we have selected 
two cetuximab-acquired resistant cell lines, such as GEO-
CR and SW48-CR, that have been previously obtained in 
our laboratory [25], and five cetuximab-primary resistant 
cell lines, such as LoVo, HCT15, SW620, SW480 and 
HCT116, that have an activating mutation in the KRAS 
gene in either codon 12 or 13 within exon 2. All cancer 
cells were exposed to escalating doses of regorafenib 
(range, 0.005–2 µM) or silybin (range, 10–100 µM), for 96 
hours and the effects on cell proliferation were evaluated 
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay. The drug concentrations required 
to inhibit cell growth by 50% (IC50) were determined by 
interpolation from the dose-response curves. As shown 
in Figure 1A–1B, there was a differential sensitivity to 
regorafenib-induced cell growth inhibition. In fact, three 
colon cancer cell lines (HCT116, SW620 and LoVo) 
were the most sensitive to regorafenib treatment, with 
IC50 values ranging from 0.5 µM (HCT116 and SW620) 
to 2 µM (LoVo). Silybin had no anti-proliferative effects 
among the colon cell lines harboring KRAS, NRAS, BRAF, 
or PIK3CA mutations (Figure 1B–1C). 
Effects of regorafenib in combination with 
silybin on cell proliferation in a panel of human 
colon cancer cell lines
We next evaluated the anti-proliferative activity of 
regorafenib in combination with silybin in the panel of 
human colon cancer cell lines. In particular, cancer cells 
were treated with two different concentrations of silybin, 
60 and 90 µM, with increasing doses of regorafenib 
(range, 0.005–2 µM) for 96 hours. In all cancer cell 
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lines tested, except for the cetuximab-sensitive LIM1215 
cells, combined treatments determined a significant 
anti-proliferative effect in a dose-dependent manner as 
compared to single treatments (Supplementary Figure 1). 
In particular, while regorafenib treatment had no effect 
on cell growth in HCT115 cells, the combined treatment 
with regorafenib 0.01 µM and silybin 90 µM restored the 
sensitivity of HCT115 cells to regorafenib (Supplementary 
Figure 1). Moreover, no significant differences were 
observed between 60 and 90 µM of silybin.
Effects of regorafenib treatment in combination 
with silybin on colony formation of SW48, 
SW48-CR, HCT15 and SW480 colon cell lines
To further evaluating the anti-cancer activity of 
combined treatment, we performed a colony formation 
assay. To do this, we selected four cell lines with different 
mutation profile for KRAS gene (SW48, SW48-CR, 
HCT15 and SW480 cells) and in which the treatment 
induced a stronger anti-proliferative effect compared 
to all cells tested. Hence, cancer cells were treated with 
silybin (90 µM) and regorafenib (2 µM) as single agents 
or in combination for 72 hours.After14 days colonies were 
stained with crystal violet and counted (Figure 2A–2B). In 
the control group, cancer cells formed large cell clusters 
within 48 hours. On the contrary, combination treatment 
reduced significantly the number of colonies compared to 
control and to single agent in all cancer cell lines.
Effects of regorafenib treatment in combination 
with silybin on cell metabolism in SW48, SW48-
CR, HCT15 and SW480 colon cell lines
We investigated the effect of combined treatment 
on cell metabolism by evaluating the reactive oxygen 
species (ROS) production in cancer cells. Oxidative stress 
occurs in cells when the generation of ROS overwhelms 
the cell natural antioxidant defenses. Several studies have 
demonstrated that several anti-cancer drugs could lead to 
ROS production and that this effect could play an important 
role in their anti-cancer activity [26–27]. The ROS 
accumulation was evaluated by dihydroethidium (DHE) 
assay using flow cytometry in SW48, SW48-CR, HCT15 
and SW480 cells. As shown in Figure 2C–2D, ROS levels 
significantly increased following combination treatment 
in all cells; whereas single treatments had no effect on 
intracellular ROS generations. These data suggest that 
combined treatment of regorafenib plus silybin increases the 
production of ROS and accumulation of superoxide anions.
Figure 1: Effects of regorafenib or silybin treatment on cell proliferation in a panel of human colon cancer cell lines. 
(A–C) Cells were treated with different concentrations of regorafenib (range, 0.005–2 µM) or silybin (range, 10–100 µM) for 96 hours. The 
proliferation rate was evaluated by MTT assay, as described in Materials and Methods. (B) The IC50 value was determined by interpolation 
with dose-response curves. Results represent the mean of three separate experiments, each performed in duplicate. 
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Effect of regorafenib treatment in combination 
with silybin on apoptosis induction in SW48, 
SW48-CR, HCT15 and SW480 cells
Furthermore, we measured the ability of regorafenib 
and silybin in combination to induce apoptosis by using 
Annexin V-FITC assay. As depicted in Figure 3A, 
compared to single agents, the combined treatment 
induced significantly more early and late apoptosis within 
24 hours of treatment in all colon cells. In particular, 
SW48 cells showed an apoptotic rate of 22% and 
34%,with regorafenib or silybin treatment, respectively; 
whereas the combined treatment induced an apoptotic rate 
of 62%. To further expand these results, the activation 
status of different pro-apoptotic factors was examined 
by western blotting. The combined treatment with 
regorafenib and silybin substantially induced the cleavage 
of PARP fragment in all cell lines (Figure 3B). Moreover, 
we observed a strong increasing in expression levels of 
caspase 3 and pro-caspase 9 in SW48, SW48-CR and 
HCT15 cells, suggesting a probable activation of extrinsic 
apoptotic mechanisms involving caspase 9- independent 
and caspase 3-dependent pathway in these cell lines [28]. 
Conversely, the expression levels of both caspases were 
approximately the same in SW480 cells and this effect 
could be explained by the activation of caspase 9- and 
caspase 3- independent mechanisms. Further experiments 
are needed to clarify the mechanisms involved in apoptosis 
process after regorafenib and silybin treatment.
Effects of regorafenib treatment in combination 
with silybin on PI3K/AKT/mTOR intracellular 
pathway in SW48, SW48-CR, HCT15 and 
SW480 cells
To examine the mechanisms by which the combined 
treatment inhibit cancer cell proliferation, the activation 
of the PI3K/AKT/mTOR pathway was evaluated. The 
SW48, SW48-CR, HCT15 and SW480 cells were treated 
with silybin (90 mM) or regorafenib (2 mM) or with their 
combination for 24 hours. The activation of PI3K/AKT/
mTOR signaling was analyzed by western blot analysis. 
Figure 2: Effect of regorafenib in combination with silybin on colony formation and on cell metabolism in SW48, 
SW48-CR, HCT15 and SW480 colon cancer cells lines. The SW48, SW48-CR, HCT15 and SW480 cancer cells were treated 
with silybin (90 µM) or regorafenib (2 µM) and their combination for 72 hours. After 14 days the colonies were stained with 0.1% crystal 
violet and counted as described in Materials and Methods. (A) Images of colon cancer cells acquired by phase-contrast microscope. 
(B) Histogram of colony number counted by image j plugin. Error bars indicate the standard deviation. *p < 0.05 compared to single 
treatment. The effects of treatments were also evaluated in terms of oxidative stress generation as described in Materials and Methods. 
(C)  Histogram of DHE mean fluorescence intensity (% of control). Error bars indicate the standard deviation. *p < 0.05 compared to 
positive control. (D) Flow cytometry overlay of dihydroethidium (DHE) fluorescence intensity within HCT15 cells. 
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As shown in Figure 4, the combined treatment induced a 
significant inhibition of the expression of the total form 
of the AKT protein as compared to single treatment. 
Interestingly, the combination of regorafenib plus silybin 
substantially inhibited the phosphorylation of AKT 
(pAKT) in all cancer cells. In addition, we studied also the 
expression of ribosomal S6 kinase (p70-S6K) and 4EB-
P1 protein (p4EB-P1), two major effectors of PI3K/AKT/
mTOR signaling. We observed a greater inhibition of p70-
S6K and p4EB-P1 after combination treatment compared 
to regorafenib or silybin alone. This effect was more 
evident in SW48, HCT15 and SW480 cells (Figure 4).
Clinical activity and tolerability of regorafenib in 
combination with silybin in metastatic colorectal 
cancer patients
To evaluate if silybin could increase the clinical 
efficacy and the toxicity profile of regorafenib, a pilot 
single arm clinical study was conducted. From November 
2013 to March 2017 twenty-two mCRC patients after 
failure of all available treatments including anti-angiogenic 
drugs and anti-EGFR monoclonal antibodies (in RAS 
wild type disease) were treated with regorafenib. Silybin-
vitamin E-phospholipids complex (188 mg of silybin, 
388 mg of phosphatidylcholine, and 60 mg of vitamin E/
day) was added to regorafenib treatment at the occurrence 
of liver toxicity.Baseline demographics, clinical and 
pathologic characteristics are listed in Supplementary 
Table 1. In this respect, 17 out of 22 patients (77%) had 
a history of metastatic disease longer than 18 months and 
in 17 patients (77%) the number of metastatic sites were 
≥ 2. Eleven out of 22 patients (50%) received ≥ 3 therapies 
for treatment of metastatic disease before regorafenib. The 
performance status (PS) according to ECOG scale was 
0 in 14 patients (64%) (Supplementary Table 1). In these 
patients, a median PFS of 10.0 months (mo) (CI95%: 4.7–
15.1) [CI 95%: 4.7–15.1 mo] and a median OS of 17.6 
mo [CI 95%; 6.2–28.9 mo] were observed, respectively 
(Figure 5). Four out of 22 patients (18%) started silybin 
concomitantly with the first dose of regorafenib. Two of 
these patients started with one dose level reduction of 
regorafenib (120 mg) because of baseline liver impairment 
(G2 blood bilirubin increase and G1 increase in blood 
levels of AST and ALT) and did not require any further 
regorafenib dose reduction during treatment. The other 
two patients started with a dose of 80 mg of regorafenib 
(two dose level reductions) because of concomitant PS 2, 
according to ECOG scale, G2 hyperbilirubinemia andG1 
hypertransaminasemia (Supplementary Table 2). Three 
of these 4 patients are, as of May 16, 2016, receiving 
the combined treatment with regorafenib and silybin. 
Eighteen out of 22 patients (82%) started treatment with 
silybin at the occurrence of liver toxicity, mainly during 
the second week of treatment and this was continued 
until disease progression (Figures 6 and 7). Eighteen out 
of 22 patients (82%) required a reduction of regorafenib 
dose during treatment. In particular, sixteen patients 
(72%) required a dose reduction of regorafenib during 
the first three cycles, mainly for hyperbilirubinemia and/
or hypertransaminasemia (85%) or for hand and foot skin 
reactions (HFSR) (15%), whereas in 2 patients (9%) the 
Figure 3: Effects of regorafenib in combination with silybin on induction of apoptosis in SW48, SW48-CR, HCT15 
and SW480 colon cancer cells. (A) Apoptosis was evaluated with Annexin-V-FITC staining and 7-Amino-Actinomycin D (7-AAD) 
detection assays using flow cytometry in SW48, SW48-CR, HCT15 and SW480 cancer cells after 24 hours of incubation with silybin 
(90 μM) or regorafenib (2 μM) and their combination. Histogram of data expressed as percentage of apoptotic cells.*p < 0.05 compared 
to single treatment. (B) Colon cancer cells were treated with silybin (90 µM) or regorafenib (2 µM) and their combination for 24 hours. 
Expression of PARP, caspase 3 and 9 were evaluated by immunoblotting as described in Materials and Methods. α-Tubulin was used as the 
loading control.
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dose was reduced after the third cycle of treatment for 
HSFR and fatigue. Six patients out of 22 (27%) needed 
one dose level reduction of regorafenib (120 mg), while 
12 patients (55%) required 2 dose levels reduction 
(80mg) (Supplementary Table 2).When the median values 
of transaminase and bilirubin blood levels in patients 
treated with regorafenib were evaluated, an increase 
from baseline to the second week of the first cycle of 
treatment with regorafenib was observed, whereas a rapid 
reduction in transaminase and bilirubin blood levels was 
found once treatment with silybin was started (Figure 7). 
The effect of silybin on restoring hepatic function was 
significant for both the normalization of AST and ALT 
levels (p < .0001) and for the reduction of bilirubin levels 
(p = 0.035). No unexpected toxicities were observed with 
the combined treatment with regorafenib and silybin. The 
reason of discontinuation from regorafenib treatment was 
radiological progression of disease in 14 out of 22 patients 
(64%), while eight patients (36%) are still on treatment. 
We did not observe any discontinuation of treatment due 
to adverse events.
DISCUSSION
The development of molecularly targeted therapies 
has provided novel opportunities for improving and 
personalizing the treatment of mCRC. In this scenario, the 
multikinase inhibitor regorafenib was demonstrated, as 
compared to placebo, to significantly increase median OS 
in two large phase III randomized trials in chemorefractory 
mCRC patients. However, the toxicity profile, in particular 
liver toxicity, as well as the lack of predictive biomarkers 
of response, limits its use in clinical practice.
Several experimental studies have provided 
evidence for anti-inflammatory and anti-oxidative 
effects of silybin, an active constituent of the milk 
thistle seeds of Silybum marianum, for the potential 
treatment of liver diseases, including protection of liver 
Figure 4: Effects of regorafenib in combination with silybin on PI3K/AKT/mTOR intracellular signaling in SW48, 
SW48-CR, HCT15 and SW480 colon cancer cell lines. SW48, SW48-CR, HCT15 and SW480 cancer cells were treated with 
silybin or regorafenib and their combination at the indicated doses for 24 hours. Total cell protein extracts were subjected to immunoblotting 
with the indicated antibodies as described in Materials and Methods. α-Tubulin was used as the loading control. 
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function damage by drugs, such as cytotoxic anti-cancer 
agents [9–10]. Moreover, it has been suggested a direct 
silybin cell growth inhibitory activity on several tumor 
types, including prostate, skin, bladder and lung cancers 
[11–15]. In the present study, we have evaluated the 
potential role of regorafenib and silybin combination 
as a novel strategy for the treatment of mCRC patients. 
Here we provide evidence for a synergic anti-proliferative 
effect of combined treatment in a panel of human colon 
cancer cell lines. In fact, the treatment of regorafenib plus 
silybin induced a stronger inhibition of cell proliferation 
compared to regorafenib and silybin alone. Furthermore, 
we demonstrated an increasing in ROS production and 
apoptotic rate after combined treatment in several colon 
cancer models. 
With a therapeutic perspective, we have 
performed an exploratory proof of concept clinical 
study, in which we have assessed the clinical activity 
of regorafenib plus silybin in a consecutive cohort of 
22mCRC patients, that were eligible for regorafenib 
Figure 5: Kaplan–Meier analysis of Progression-Free Survival (PFS) and Overall Survival (OS) in the overall 
population. 
Figure 6: Progression Free Survival (PFS) in the overall population. Patients 1-2-5-6-11-12-15-21: treatment was ongoing at 
the time of data cutoff; Patients 3-5-11-12 received silybin treatment from the first cycle due to basal hypertransaminasemia. 
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treatment after failure of all available standard anti-
cancer therapies. A median PFS of 10.0 mo [CI 95%: 
4.7–15.1 mo] and a median OS of 17.6 mo [CI 95%; 
6.2–28.9 mo] were observed in these patients. Although 
these results derive from a small size, single arm, proof 
of concept, prospective clinical study and although 
they need to be confirmed and validated in appropriate 
larger and randomized studies, they suggest that silybin 
addition to regorafenib treatment in mCRC patients 
that have failed all available anti-cancer treatments 
could potentially increase the anti-tumor efficacy of 
regorafenib. Furthermore, another potentially relevant 
clinical implication of this study is the evidence that 
addition of silybin to regorafenib treatment at the 
occurrence of regorafenib-induced liver toxicity, was 
associated with a statistically significant decreasing in 
the serum level of AST, ALT and bilirubin. Therefore, 
silybin could protect the patient from liver damage 
induced by regorafenib and, therefore, could allow to 
continue a potentially effective anti-cancer therapy. 
MATERIALS AND METHODS
Drugs
Silybin was provided by Indena (Milan, Italy).
Regorafenib was kindly provided by Bayer Pharma 
(Berlin, Germany). For in vitro studies, silybin and 
regorafenib were dissolved in sterile dimethyl sulfoxide 
(DMSO) and the stock solution (10 mmol/L) was stored 
in aliquots at –20°C. The working solution was diluted in 
culture medium just before each experiment. 
Cell lines
The human SW48 colon cancer cell (KRAS, NRAS, 
BRAF and PIK3CA wild-type profile) was obtained from 
IRCCS “Azienda Ospedaliera Universitaria San Martino-
IST Istituto Nazionale per la Ricerca sul Cancro, Genova” 
Italy. The human GEO colon cancer cell line (KRAS 
mutation (G12A); NRAS, BRAF, and PIK3CA WT was 
Figure 7: Total bilirubin, AST and ALT plasma levels (mean ±) in the overall population  during treatment with 
regorafenib and silybin.
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kindly provided by Dr. N. Normanno (National Cancer 
Institute, Naples, Italy). The human LIM1215 colon cells 
(KRAS, NRAS, BRAF and PIK3CA WT) was obtained from 
Dr.ssa Di Nicolantonio at Candiolo National Cancer Institute 
(Candiolo, Italy). The human HCT15, HCT116, SW480, 
LoVo and SW620 colon cancer cell lines, having different 
mutation profiles in KRAS, NRAS, BRAF, and PIK3CA genes, 
were purchased from ATCC. The GEO-CR and SW48-CR, 
were established as previously described [25]. The HCT15, 
SW480, SW48, SW48-CR, LoVo, LIM1215 and HCT116 
cancer cells were cultured with RPMI-1640 medium (Sigma-
Aldrich, Missouri, USA) supplemented with 10% fetal 
bovine serum (FBS, Sigma-Aldrich), 100 U/ml penicillin and 
100 mg/ml streptomycin. The SW620, GEO and GEO-CR 
cancer cells were routine culturing with McCoy’s medium 
(Sigma-Aldrich) supplemented with 10% FBS, 100 U/ml 
penicillin and 100 mg/ml streptomycin. The cells were 
maintained in a humidified controlled atmosphere with 95% 
to 5% ratio of air/CO2, at 37°C. The medium was changed 
every 3–4 days. 
Cell viability assay
Colon cancer cells were seeded into 24-well 
plates at the density of 1 × 104 cells/well and exposed to 
increasing concentrations of silybin (range: 10–100 µM) 
or regorafenib (range: 0.005–2 µM). For the combination 
treatments, colon cancer cells were treated with two 
concentrations of silybin (60 or 90 µM) with increasing 
doses of regorafenib (0.005 to 2 µM). The growth 
inhibition was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT, Sigma-Aldrich) assay 
after 96 h of incubation. The concentrations inhibiting 50% of 
cell growth (IC50) were obtained and these values were used 
for subsequent experiments. Results represent the median of 
three separate experiments, each performed in duplicate. 
Colony formation assay
Colony formation test was performed to evaluate 
the long-term proliferative potential of SW48, SW48-
CR, HCT15 and SW480 cells following silybin and 
regorafenib treatments. Cancer cells were seeded in 100 
mm3 cell culture dishes at the density of 3 × 103 and 
incubated with silybin (90 µM) or regorafenib (2 µM) 
and their combination for 72 hours. The medium was 
replaced with fresh culture media every 3 days. After 14 
days, cells were fixed with 4% paraformaldehyde at room 
temperature (RT) for 15 minutes, stained with 0.1% crystal 
violet and counted using image j plugin [29]. Results 
represent the median of two separate experiments. 
Reactive oxygen species (ROS) detection 
The evaluation of ROS accumulation was detected 
using dihydroethidium (DHE) assay by flow cytometry 
(BD Accuri™ C6 Plus) [30]. Once oxidezed within cells, 
DHE was converted into ethidium (HE) and emits at 605 
nm. Briefly, the SW48, SW48-CR, HCT15 and SW480 
cancer cells were seeded in 6-well plates (1× 105 cells/
well) and treated with silybin (90 µM) or regorafenib (2 
µM) and their combination for 24 hours. Cancer cells were 
also treated with 250 μM of H2O2 as positive control of 
cytotoxicity. As a negative control, we applied the same 
assay onto untreated cells. At the end of each treatment, 
all cancer cells were incubated with 20 ng/mL DHE 
stock solutions (2.5 mg/mL) for 1 hours. At the time of 
processing, cells were harvested, washed twice with PBS 
1X and the pellet was suspended in 500 μl of PBS 1X. 
The dye accumulation was measured using BD Accuri™ 
C6 (BD Bioscences) flow cytometer and analyzed by BD 
Accuri™ C6software. For each sample, 1 × 104 events 
were acquired. Results represent the median of three 
separate experiments, each performed in duplicate. 
Apoptosis assay
Apoptotic cell death was analyzed using Annexin-
V-FITC and 7-Amino-Actinomycin D (7-AAD) detection 
assays (Invitrogen). Briefly, SW48, SW48-CR, HCT15 
and SW480 were seeded in 6-well plates at the density 
of 2 × 105 cells/well with the same concentrations used 
for ROS evaluation. After 24 h of treatment, cells were 
harvested, centrifuged for 5 minutes at 1200 RPM and 
the pellets were suspended in 100 μL 1X Annexin buffer 
solution. Then, 5 μL Annexin V-FITC and 10 μL 7-AAD 
(100 μg/ml) were added to cell suspension at RT for 
15 minutes. The detection of viable cells, early and late 
apoptosis cells, and necrotic cells were performed by BD 
Accuri™ C6 (BD Bioscences) flow cytometer following 
the manufacturer’s protocol. For each sample, 1 × 104 
events were acquired. Results represent the median of 
three separate experiments, each performed in duplicate. 
Immunoblotting
The SW48, SW48-CR, HCT15 and SW480 cancer 
cells were seeded into 100 mm3 petri dishes and treated 
for 24 h with silybin or regorafenib and their combination, 
as previously indicated. Cells were lysed with RIPA 
lysis buffer (Sigma-Aldrich, MO, USA) with protease 
and phosphatase inhibitors cocktail. Protein extracts 
were then quantified by using Bradford assay (BioRad, 
CA, USA), according to the manufacturer’s instruction. 
Equal amounts of total proteins were separated by 4–15% 
gradient mini precast TGX gel (BioRad) and transferred 
to nitrocellulose membrane (BioRad). The membrane was 
blocked with 5% of milk at RT for 1 hours and incubated 
with following primary polyclonal antibodies Caspase 
3 (#9662), PARP (#9542), AKT (#9272), p70-S6K 
(#9205) and monoclonal antibodies Caspase 9 (#9508), 
p-AKT (#4060) and p4EB-P1 (#2855) purchased from 
Cell Signaling (Beverly, MA, USA). Monoclonal anti-
α-tubulin antibody was provided by Sigma-Aldrich (St. 
Oncotarget68314www.impactjournals.com/oncotarget
Louis, MO, USA). After incubation with secondary anti-
goat antibody at room temperature for 1 hours, according 
to the manufacturer’s instruction, the membranes were 
developed using an enhanced chemiluminescence (ECL) 
detection system (Invitrogen, CA, USA). Each experiment 
was done in duplicate.
Clinical study: patient population
We performed a single institution, exploratory 
proof of concept, single arm clinical study to assess the 
clinical activity of regorafenib in combination with silybin 
in mCRC patients, after failure of standard therapies 
including fluoropyrimidine, oxaliplatin, irinotecan, 
anti-VEGF therapy and anti-EGFR drugs if RAS WT. 
Regorafenib was administrated at a dose of 160 mg/
day for the first 3 weeks q28, whereas silybin-vitamin 
E-phospholipids complex (188 mg of silybin, 388 mg of 
phosphatidylcholine, and 60 mg of vitamin E/day) was 
administered continuously, starting at the appearance of 
liver toxicity, defined as grade 1 (G1) increased level of 
blood bilirubin and/or G1 increased levels of aspartate 
aminotransferase (AST) or alanine aminotransferase 
(ALT), according  to National Cancer Institute Common 
Terminology Criteria for Adverse Events (CTCAE), 
version 4.03. The study population consisted of a 
consecutive cohort of 22 patients, older than 18 years with 
histological confirmed adenocarcinoma of the colon or 
rectum, Eastern Cooperative Oncology Group (ECOG) 
performance status (PS) of 0–2. Data were collected from 
patients who received at least one regorafenib and one 
silybin dosefrom November 2013 to a data cut-off of the 
15th of March 2017. Baseline demographic and clinical 
characteristics are listed in  Supplementary Table 1. All 
patients provided informed consent before receiving the 
first dose of regorafenib. Severity of adverse events (AEs) 
was graded using the CTCAE, version 4. We performed a 
weekly clinical visit during the first month with a physical 
and biochemistry assessment. Tumor response was 
evaluated every 8 weeks and assessed according to the 
Response Evaluation Criteria in Solid Tumors (RECIST 
1.1).OS, PFS and safety were evaluated.
Statistical analysis 
Statistical analyses of the in vitro data were 
performed using a one-way analysis of variance 
(ANOVA). Quantitative data were reported as mean 
± standard deviation (SD). Results were compared by 
analysis of variance (ANOVA), and a p value < 0.05 was 
considered statistically significant. The Kaplan-Meier 
method was used to estimate median PFS and OS time 
of patient population, p values were calculated using log-
rank tests at a significance level of 5%. ANOVA test was 
used to detect mean differences on continuous variables. 
All statistical analyses were performed using IBM-SPSS 
statistics version 22.0.
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